The DERP: Is it an effective methodology?

Health Affairs

Volumn 25, Issue 4, 2006, Pages

  Heaton, Alan H ^a,b  

^a Blue Cross and Blue Shield of Minnesota   (United States)

^b Minnesota Department of Human Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DECISION MAKING; DRUG USE; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HUMAN; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PHARMACY AND THERAPEUTICS COMMITTEE; PUBLICATION; SHORT SURVEY;

COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG UTILIZATION REVIEW; EFFICIENCY, ORGANIZATIONAL; EVIDENCE-BASED MEDICINE; FORMULARIES; HEALTH CARE COALITIONS; HUMANS; PHARMACY AND THERAPEUTICS COMMITTEE;

EID: 33746882787     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.w276     Document Type: Short Survey

References (5)

1. P.J. Neumann, "Emerging Lessons from the Drug Effectiveness Review Project," Health Affairs 25 (2006): w262-w271 (published online 6 June 2006; 10.1377/hlthaff.25.w262).
2. U.S. Pharmacopeia, "USP's Initial Medicare Model Guidelines," http://www.usp.org/healthcareInfo/mmg/initialGuidelines.html (accessed 30 May 2006).
3. Centers for Medicare and Medicaid Services, "Medicare Modernization Act: 2007 Final Guidelines - Formularies," http://www.amcp.org/data/ nav_content/Final%20CY%202007%20Formulary%20Guidance%2Epdf (accessed 30 May 2006).
4. See P.J. Neumann, "Evidence-based and Value-based Formulary Guidelines," Health Affairs 23, no. 1 (2004): 124-134.
5. National Committee for Quality Assurance," What Does NCQA Review When It Accredits an HMO?" http://www.ncqa.org/Programs/Accreditation/mco/ mcostdsoverview.htm (accessed 30 May 2006).